A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations

Highlights ► One dose of cell-culture-derived, pandemic influenza vaccine adequate for adults. ► Two doses required for the elderly. Adjuvanted vaccine well tolerated in all subjects. ► Rapid production by cell-culture helps to meet global demand for pandemic vaccines.

Saved in:
Bibliographic Details
Published in:Vaccine 2012-07, Vol.30 (32), p.4820-4827
Main Authors: Hatz, Christoph, Cramer, Jakob P, Vertruyen, André, Schwarz, Tino F, von Sonnenburg, Frank, Borkowski, Astrid, Lattanzi, Maria, Hilbert, Anne Katrin, Cioppa, Giovanni Della, Leroux-Roels, Geert
Format: Article
Language:English
Subjects:
Adjuvant
adjuvants
Adjuvants, Immunologic - administration & dosage
Adolescent
Adult
Aged
Allergy and Immunology
Antibodies, Viral - blood
Antigens
cell culture
Cell Culture Techniques
Clinical trials
diagnostic techniques
elderly
Female
Fever
H1N1
Hemagglutination Inhibition Tests
Humans
immune response
Immunization, Secondary
Immunogenicity
Influenza
Influenza A Virus, H1N1 Subtype
Influenza Vaccines - adverse effects
Influenza Vaccines - biosynthesis
Influenza Vaccines - immunology
Influenza, Human - prevention & control
Male
MF59
Middle Aged
Pandemic
Pandemics
Polysorbates - administration & dosage
secondary immunization
Single-Blind Method
Squalene - administration & dosage
Swine flu
vaccination
Vaccines
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► One dose of cell-culture-derived, pandemic influenza vaccine adequate for adults. ► Two doses required for the elderly. Adjuvanted vaccine well tolerated in all subjects. ► Rapid production by cell-culture helps to meet global demand for pandemic vaccines.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2012.05.013